Effectiveness of pertussis vaccination and duration of immunity

CMAJ

Volumn 188, Issue 16, 2016, Pages E399-E406

  Schwartz, Kevin L ^a,b,c   Kwong, Jeffrey C ^a,d,e   Deeks, Shelley L ^a   Campitelli, Michael A ^a   Jamieson, Frances B ^d,f   Marchand Austin, Alex ^d,f   Stukel, Therese A ^a,b   Rosella, Laura ^a,b   Daneman, Nick ^a,b   Bolotin, Shelly ^a   Drews, Steven J ^g,h   Rilkoff, Heather ^a   Crowcroft, Natasha S ^a,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY HEALTH NETWORK   (Canada)

^f PUBLIC HEALTH ONTARIO   (Canada)

^g UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

^h UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACELLULAR VACCINE; PERTUSSIS VACCINE;

AGE DISTRIBUTION; ARTICLE; AUSTRALIA; CASE CONTROL STUDY; CHILD; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; MAJOR CLINICAL STUDY; MALE; PERTUSSIS; RURAL AREA; SCHOOL CHILD; UNITED STATES; VACCINATION; ACTIVE IMMUNIZATION; ADOLESCENT; DISEASE OUTBREAKS; INCIDENCE; INFANT; MULTIVARIATE ANALYSIS; ODDS RATIO; ONTARIO; PRESCHOOL CHILD; STATISTICAL MODEL; WHOOPING COUGH; YOUNG ADULT;

ADOLESCENT; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; DISEASE OUTBREAKS; FEMALE; HUMANS; IMMUNITY, ACTIVE; IMMUNIZATION SCHEDULE; INCIDENCE; INFANT; LOGISTIC MODELS; MALE; MULTIVARIATE ANALYSIS; ODDS RATIO; ONTARIO; PERTUSSIS VACCINE; WHOOPING COUGH; YOUNG ADULT;

EID: 84993953572     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.160193     Document Type: Article

References (39)

1. Pertussis (whooping cough): for health care professionals. Ottawa: Health Canada; modified 2014. Available: www.phac-aspc.gc.ca/im/vpd-mev/pertussis/professionals-professionnels-eng.php (accessed 2014 May 29).
2. Deeks SLLG, Walton R, Fediurek J, et al. Prolonged pertussis outbreak in Ontario originating in an under-immunized religious community. Can Commun Dis Rep 2014;40;42-9.
3. Bentsi-Enchill AD, Halperin SA, Scott J, et al. Estimates of the effectiveness of a whole-cell pertussis vaccine from an outbreak in an immunized population. Vaccine 1997;15:301-6.
4. De Serres G, Boulianne N, Duval B, et al. Effectiveness of a whole cell pertussis vaccine in child-care centers and schools. Pediatr Infect Dis J 1996;15:519-24.
5. Halperin SA, Bortolussi R, MacLean D, et al. Persistence of pertussis in an immunized population: results of the Nova Scotia Enhanced Pertussis Surveillance Program. J Pediatr 1989; 115:686-93.
6. Publicly Funded Immunization Schedules for Ontario-October 2015. Toronto: Ministry of Health and Long-Term Care; 2015. Available: www.health.gov.on.ca/en/pro/programs/immunization/docs/immunization-schedule.pdf (accessed 2016 Sept. 12).
7. Vickers D, Ross AG, Mainar-Jaime RC, et al. Whole-cell and acellular pertussis vaccination programs and rates of pertussis among infants and young children. CMAJ 2006;175:1213-7.
8. Klein NP, Bartlett J, Fireman B, et al. Comparative effectiveness of acellular versus whole-cell pertussis vaccines in teenagers. Pediatrics 2013 ;131:1716-22.
9. Sheridan SL, Ware RS, Grimwood K, et al. Number and order of whole cell pertussis vaccines in infancy and disease protection. JAMA 2012;308:454-6.
10. Klein NP, Bartlett J, Rowhani-Rahbar A, et al. Waning protection after fifth dose of acellular pertussis vaccine in children. N Engl J Med 2012;367:1012-9.
11. Baxter R, Bartlett J, Rowhani-Rahbar A, et al. Effectiveness of pertussis vaccines for adolescents and adults: case-control study. BMJ 2013;347:f4249.
12. Kwong JC, Campitelli MA, Gubbay JB, et al. Vaccine effectiveness against laboratory-confirmed influenza hospitalizations among elderly adults during the 2010-2011 season. Clin Infect Dis 2013;57:820-7.
13. Jackson ML, Nelson JC. The test-negative design for estimating influenza vaccine effectiveness. Vaccine 2013;31:2165-8.
14. De Serres G, Skowronski DM, Wu XW, et al. The test-negative design: validity, accuracy and precision of vaccine efficacy estimates compared to the gold standard of randomised placebocontrolled clinical trials. Euro Surveill 2013;18:pii: 20585.
15. Fisman DN, Tang P, Hauck T, et al. Pertussis resurgence in Toronto, Canada: a population-based study including testincidence feedback modeling. BMC Public Health 2011; 11:694.
16. Guthrie JL, Seah C, Brown S, et al. Use of Bordetella pertussis BP3385 to establish a cutoff value for an IS481-targeted realtime PCR assay. J Clin Microbiol 2008;46:3798-9.
17. Guthrie JL, Robertson AV, Tang P, et al. Novel duplex realtime PCR assay detects Bordetella holmesii in specimens from patients with pertussis-like symptoms in Ontario, Canada. J Clin Microbiol 2010;48:1435-7.
18. Ducharme R, Benchimol EI, Deeks SL, et al. Validation of diagnostic codes for intussusception and quantification of childhood intussusception incidence in Ontario, Canada: a population-based study. J Pediatr 2013;163:1073-9.e3.
19. Schwartz KL, Tu K, Wing L, et al. Validation of infant immunization billing codes in administrative data. Hum Vaccin Immunother 2015;11:1840-7.
20. Iron K, Zagorski BM, Sykora K, et al. Living and dying in Ontario: an opportunity for improved health information. ICES investigative report. Toronto: Institute for Clinical Evaluative Sciences; 2008.
21. Finkelstein MM. Ecologic proxies for household income: How well do they work for the analysis of health and health care utilization? Can J Public Health 2004;95:90-4.
22. Feudtner C, Christakis DA, Connell FA. Pediatric deaths attributable to complex chronic conditions: a population-based study of Washington State, 1980-1997. Pediatrics 2000;106: 205-9.
23. McGirr A, Fisman DN. Duration of pertussis immunity after DTaP immunization: a meta-analysis. Pediatrics 2015;135: 331-43.
24. Orenstein WA, Bernier RH, Dondero TJ, et al. Field evaluation of vaccine efficacy. Bull World Health Organ 1985;63:1055-68.
25. Fox MP, Lash TL, Greenland S. A method to automate probabilistic sensitivity analyses of misclassified binary variables. Int J Epidemiol 2005;34:1370-6.
26. Misegades LK, Winter K, Harriman K, et al. Association of childhood pertussis with receipt of 5 doses of pertussis vaccine by time since last vaccine dose, California, 2010. JAMA 2012; 308: 2126-32.
27. Tartof SY, Lewis M, Kenyon C, et al. Waning immunity to pertussis following 5 doses of DTaP. Pediatrics 2013;131: e1047-52.
28. Liko J, Robison SG, Cieslak PR. Pertussis vaccine performance in an epidemic year-Oregon, 2012. Clin Infect Dis 2014;59:261-3.
29. Tomovici A, Barreto L, Zickler P, et al. Humoral immunity 10 years after booster immunization with an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine. Vaccine 2012;30:2647-53.
30. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine from the Advisory Committee on Immunization Practices, 2010. MMWR Morb Mortal Wkly Rep 2011;60:13-5.
31. Canadian Immunization Guide: Part 4, active vaccines: pertussis vaccine (February 2014). Ottawa: Public Health Agency of Canada; 2014. Available: www.phac-aspc.gc.ca/publicat/cig-gci/p04-pert-coqu-eng.php (accessed 2015 Mar. 1).
32. Immunization coverage report for school pupils: 2012-2013. Toronto: Public Health Ontario; 2014. Available: www.public healthontario.ca/en/eRepository/Immunization-coverage-report-2012-13.pdf (accessed 2016 Feb. 8).
33. Vaccine coverage amongst adult Canadians: results from the 2012 adult National Immunization Coverage (aNIC) survey. Ottawa: Public Health Agency of Canada; modified 2014. Available: www.phac-aspc.gc.ca/im/nics-enva/vcac-cvac-eng. php (accessed 2016 Feb. 8).
34. Amirthalingam G, Andrews N, Campbell H, et al. Effectiveness of maternal pertussis vaccination in England: an observational study. Lancet 2014;384:1521-8.
35. Reyes IS, Hsieh DT, Laux LC, et al. Alleged cases of vaccine encephalopathy rediagnosed years later as Dravet syndrome. Pediatrics 2011;128:e699-702.
36. Berkovic SF, Harkin L, McMahon JM, et al. De-novo mutations of the sodium channel gene SCN1A in alleged vaccine encephalopathy: a retrospective study. Lancet Neurol 2006;5: 488-92.
37. DeAngelis H, Scarpino SV, Fitzpatrick MC, et al. Epidemiological and economic effects of priming with the whole-cell Bordetella pertussis vaccine. JAMA Pediatr 2016;170:459-65.
38. Riolo MA, Rohani P. Combating pertussis resurgence: one booster vaccination schedule does not fit all. Proc Natl Acad Sci U S A 2015;112:E472-7.
39. Bolotin S, Deeks SL, Marchand-Austin A, et al. Correlation of real time PCR cycle threshold cut-off with Bordetella pertussis clinical severity. PLoS One 2015;10:e0133209.